Welcome to our dedicated page for Crawford & Company news (Ticker: CRD-A), a resource for investors and traders seeking the latest updates and insights on Crawford & Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crawford & Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crawford & Company's position in the market.
Crawford & Company (CRD-A) reported Q1 2020 financial results, showing revenues of $237.5 million, a decrease from $247.1 million in Q1 2019. The company incurred a net loss of $11.4 million, compared to a profit of $6.1 million a year prior. GAAP diluted loss per share was $(0.21) for CRD-A. Non-GAAP revenues were $238.8 million, with net income of $1.0 million, down from $6.1 million in Q1 2019. A goodwill impairment of $17.7 million and restructuring costs of $5.7 million were recorded, primarily due to impacts from COVID-19 and reduced claims activity.
Summary not available.